Novo Nordisk A/S (BCBA:NVOD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 275.94T -12.1% |
| Revenue (ttm) | 74.58T +5.6% |
| Net Income | 26.36T +4.8% |
| EPS | 865.16 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.04 |
| Forward PE | 12.13 |
| Dividend | 78.29 (0.82%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 515 |
| Open | 5.94 |
| Previous Close | 6.03 |
| Day's Range | 5.94 - 6.21 |
| 52-Week Range | 5.50 - 7.83 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk warns on Irish access to obesity drug after US pricing deal
Danish pharmaceutical giant, which is awaiting a HSE decision on Wegovy cover, met with the public spending minister in March
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.
Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.
Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial
Eli Lilly said on Wednesday its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk’s Ozempic on blood sugar control and delivered more than double the weight loss in a d...
Novo Stock (NVO) Falls After Another Head-to-Head Obesity Trial Loss to Eli Lilly
Shares of Danish pharma giant Novo ($NVO) edged lower to around $38 on Wednesday afternoon. This came after rival drugmaker Eli Lilly ($LLY) announced results of a head-to-head trial in…
Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial
Eli Lilly's experimental next-generation drug retatrutide outperformed a lower-dose version of Novo Nordisk's Ozempic on blood sugar control and showed more than double weight loss in a study of adult...
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
NVO Stock Is Trading Near Its 52-Week Low. Here’s Why That Number Tells Only Part of the Story.
Novo Nordisk was the most talked-about pharmaceutical company in the world not too long ago. Ozempic had evolved from a diabetes drug into a cultural icon. Wegovy was being discussed at dinner… The po...
US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk
A US judge on Monday rejected Novo Nordisk's request to block Eli Lilly from continuing weight-loss drug advertisements that the Danish drugmaker considered false and misleading.
Novo Nordisk A/S Reports Share Repurchase Transactions Under DKK 15 billion Programme
Novo Nordisk A/S has announced transactions under its share repurchase programme. On 6 May 2026, the company initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/20...
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
The S&P 500 remains in a confirmed uptrend, yet a big slice of the market isn't along for the ride. Money keeps crowding into the same mega-cap leaders, and plenty of solid companies sit below their 5...
FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older
The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10…
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimated, as improving affordability and broader access drive...
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.
Where Will Novo Stock Be in 10 Years?
Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
Novo Nordisk stock gained on Tuesday alongside new weight-loss data from women who used CagriSema.
Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
Novo Nordisk shares NVO rose on Tuesday after the Danish drugmaker reported that its experimental weight-loss drug CagriSema helped women with obesity or overweight lose an average of 25% of their bod...
Novo Nordisk Reports 25% Weight Loss With CagriSema In Women; Stock Up
(RTTNews) - Novo Nordisk (NVO) reported results from two post hoc analyses of its Phase 3 REDEFINE 1 trial, showing that investigational CagriSema was associated with an average weight loss of 25% at ...
Novo Nordisk CagriSema Shows Significant Weight Loss Across Menopause Stages
(RTTNews) - Novo Nordisk (NVO) reported results from two post hoc analyses of its Phase 3 REDEFINE 1 trial, showing that investigational CagriSema was associated with an average weight loss of 25% at ...
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy. The Danish company said its next-generation ...
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on average in women with obesity or overweight, according to data analyzed after the completion of...
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 19 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A new government-funded study found that GLP-1 drugs slow the aging process in mice.
Eli Lilly's weight-loss pill wins EU drug regulator's backing
The European Medicines Agency's committee on Friday recommended approval of Eli Lilly's weight-loss pill Foundayo, making it the second oral weight-loss drug to win the agency's backing after Novo Nor...